预测下腔静脉滤器的安全性和有效性(PRESERVE):12个月结局
PRESERVE研究为前瞻性非随机研究,2015年10月10日至2019年3月31日在美国54个中心纳入1429例参与者,评估下腔静脉滤器(VCF)的安全性和有效性。1421例植入VCF,主要安全终点和主要有效性终点均达到;VCF相关不良事件罕见(7/1421,0.5%),无致死性肺栓塞发生。作者认为VCF植入与少量不良事件及低临床显著肺栓塞发生率相关。
要点
- 1421例植入VCF,主要安全终点和主要有效性终点均达到。
- VCF相关不良事件罕见(7/1421,0.5%),但1例在尝试取出VCF时死亡。
- 滤器置入后静脉血栓栓塞事件93例(6.5%),均无致死性。
核心结论
- 在静脉血栓栓塞症患者中植入VCF与少量不良事件及低临床显著肺栓塞发生率相关。
研究设计与样本
- 前瞻性非随机研究,2015年10月10日至2019年3月31日在美国54个中心纳入1429例参与者(62.7 ± 14.7岁;762例[53.3%]男性),1421例植入VCF。
主要发现
- 1019例(71.7%)有当前深静脉血栓和/或肺栓塞,1159例(81.6%)抗凝治疗禁忌或失败,126例(8.9%)为预防性置入。
- 632例(44.5%)取出VCF,平均取出时间101.5 ± 72.2天,中位86.3天。
- 排除核心实验室可用的201例CT中31例(15.4%)>5 mm的支柱穿孔(其中仅3例[0.2%]被中心研究者认为有临床意义),VCF相关不良事件罕见(7/1421,0.5%)。
- 滤器置入后静脉血栓栓塞事件93例(6.5%),包括深静脉血栓74例(5.2%,80次事件)、肺栓塞23例(1.6%,23次事件)、腔静脉血栓闭塞15例(1.1%,15次事件),均无致死性;预防性置入后无肺栓塞发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the safety and effectiveness of vena cava filters (VCFs). METHODS: A total of 1429 participants (62.7 ± 14.7 years old; 762 [53.3% male]) consented to enroll in this prospective, nonrandomized study at 54 sites in the United States between October 10, 2015, and March 31, 2019. They were evaluated at baseline and at 3, 6, 12, 18, and 24 months following VCF implantation. Participants whose VCFs were removed were followed for 1 month after retrieval. Follow-up was performed at 3, 12, and 24 months. Predetermined composite primary safety (freedom from perioperative serious adverse events [AEs] and from clinically significant perforation, VCF embolization, caval thrombotic occlusion, and/or new deep vein thrombosis [DVT] within 12-months) and effectiveness (composite comprising procedural and technical success and freedom from new symptomatic pulmonary embolism [PE] confirmed by imaging at 12-months in situ or 1 month postretrieval) end points were assessed. RESULTS: VCFs were implanted in 1421 patients. Of these, 1019 (71.7%) had current DVT and/or PE. Anticoagulation therapy was contraindicated or had failed in 1159 (81.6%). One hundred twenty-six (8.9%) VCFs were prophylactic. Mean and median follow-up for the entire population and for those whose VCFs were not removed was 243.5 ± 243.3 days and 138 days and 332.6 ± 290 days and 235 days, respectively. VCFs were removed from 632 (44.5%) patients at a mean of 101.5 ± 72.2 days and median 86.3 days following implantation. The primary safety end point and primary effectiveness end point were both achieved. Procedural AEs were uncommon and usually minor, but one patient died during attempted VCF removal. Excluding strut perforation greater than 5 mm, which was demonstrated on 31 of 201 (15.4%) patients' computed tomography scans available to the core laboratory, and of which only 3 (0.2%) were deemed clinically significant by the site investigators, VCF-related AEs were rare (7 of 1421, 0.5%). Postfilter, venous thromboembolic events (none fatal) occurred in 93 patients (6.5%), including DVT (80 events in 74 patients [5.2%]), PE (23 events in 23 patients [1.6%]), and/or caval thrombotic occlusions (15 events in 15 patients [1.1%]). No PE occurred in patients following prophylactic placement. CONCLUSIONS: Implantation of VCFs in patients with venous thromboembolism was associated with few AEs and with a low incidence of clinically significant PEs.
引用
- Johnson MS, Spies JB, Scott KT, et al. Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36872169. doi:10.1016/j.jvsv.2022.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。